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Abstract
Microbial natural products possess a wide range of biological and biochemical potential. Among them, fungal secondary
metabolites are one of the most important sources for discovering new drugs or lead compounds. In the present study,
we explored substances produced by the strain Penicillium sp. FKI-7127 for its antiviral activity. We identified brefeldin A
as a novel antiviral agent against dengue viruses. The inhibitory effect of brefeldin A was confirmed by virus titer and
immunofluorescence assay. Brefeldin A inhibited dengue viruses regardless of serotypes and other related viruses
including Zika virus and Japanese encephalitis virus. Time-of-addition study showed that brefeldin A exerts its
antiviral effect at an early stage of the dengue virus (DENV) life cycle. These studies demonstrate that (i) brefeldin
A could be used as a lead compound for drug development of anti-DENV and other related viruses and (ii) fungal
metabolites are a potential and valuable source for dengue virus drug discovery.
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Introduction
Dengue virus (DENV) is an important mosquito-borne
pathogen for causing dengue fever (DF) and dengue
hemorrhagic fever (DHF). DF is relatively mild, but DHF
leads to the life-threatening dengue shock syndrome [1].
It is estimated that there are 390 million dengue
infections per year, of which 96 million manifest
apparently [2]. At present, no specific antiviral therapy
for treatment of dengue disease is available. Thus, drug
discovery research for dengue is of importance.
Natural products are valuable materials for the
discovery and development of new drugs for treating
many diseases since they possess a wide range of
structural and functional diversity [3]. Among varied
sources of natural products, secondary metabolites
produced by fungi have been recognized as an important
source of lead structures for new drugs [4].
Some bioactive compounds that are isolated and charac-
terized from metabolites of soil-borne and endophytic
fungi have led to the development of drugs such as anti-
cancer drug Taxol which originated from endophytic-
fungal metabolites [5]. Furthermore, a lot of antibacterial
substances have been demonstrated from extracts and
pure substances obtained from culture broth or fungal
biomass [6]. Some studies have identified substances that
inhibit viruses [7, 8]. However, there are only few reports
about DENV compounds found from fungal metabolites
so far [9].
In this study, we examined anti-DENV activity of
secondary metabolites produced by a fungal strain, Peni-
cillium sp. FKI-7127. We isolated and identified brefel-
din A (BFA) as a novel antiviral agent against DENVs.
Inhibition of BFA on Japanese encephalitis virus (JEV)
and Zika virus (ZIKV) was also demonstrated.
Materials and methods
Cell lines and viruses
Vero cells were maintained in a minimum essential
medium supplemented with 10% fetal calf serum. The
cells were grown at 37 °C with 5% CO2. The strains used
for this study were patient-derived DENV1–4 from the
Philippines, strains 99st, 00st-22A, SLMC50, and
SLMC318, respectively; Zika virus strain 976; and
Japanese encephalitis virus (JEV) Beijing strain.
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Microorganisms and culture of the fungal strain
The fungal strain FKI-7127 was isolated from a soil
around the root of Angelica keiskei collected in Kouzu
Island, Tokyo, Japan. To observe the morphological
characteristics, this strain was incubated on Miura’s
medium (LcA). From the results of morphological
observation, the producing strain FKI-7127 was
classified as genus Penicillium. The strain Penicillium
sp. FKI-7127 was maintained on an LcA slant. A
loopful of spores of this strain was inoculated into a
test tube, containing 10 ml of a seed medium consist-
ing of 2% glucose, 0.5% Polypepton, 0.2% yeast ex-
tract, 0.2% KH2PO4, 0.05% MgSO4·7H2O, and 0.1%
agar, and incubated for 3 days. One milliliter of the
seed culture was inoculated into each of two 500-ml
Erlenmeyer flasks containing 100 ml of a production
medium consisting of 3% soluble starch, 1.0% gly-
cerol, 2% soybean meal, 0.3% dry yeast, 0.3% KCl,
0.2% CaCO3, 0.05% KH2PO4, 0.05% MgSO4·7H2O,
and 0.03% quercetin dihydrate, and the production
culture was incubated for 6 days. Fifty percent of
ethanol extract of cultured broth were prepared for
antiviral test.
Antigen detection ELISA
To evaluate the antiviral activity of a sample, Vero cells
were seeded in 96-well plates (1 × 104 cells/well) and
infected with DENV at multiplicity of infection (MOI) of
0.5 in the presence of samples/compound or 0.1%
dimethyl sulfoxide (DMSO). The cells were incubated for
3 days when infected culture fluid (ICF) was harvested
and subjected for antigen detection enzyme-linked im-
munosorbent assay (ELISA) to determine dengue virus
antigen level as described previously [10]. The result was
expressed as a percent of inhibition which determined as
(OD value of DMSO-treated cells) − (OD value of
compound-treated cells) × 100% divided by (OD value of
DMSO-treated cells).
Cells viability assay
Vero cells in 96-well plates were treated with samples
for 5 days. Cell viability was evaluated by MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide]
according to manufacturer’s instruction (Promega).
Isolation and identification of brefeldin A
Cultured broth was extracted with 200 ml of ethyl alcohol
(EtOH). After the mycelia were separated by centrifuga-
tion, the extract was evaporated to remove EtOH. A part
of the aqueous residue was applied to a Seppak plus ODS
C18 cartridge and eluted with H2O–CH3CN system to
give five fractions (pass through 100:0, 70:30, 40:60, and
0:100 each 3 ml). Brefeldin A was detected in both 40:60
fraction and 0:100 fraction by high-performance liquid
chromatography (HPLC) analysis, and identification of
brefeldin A was achieved by high-resolution electrospray
ionization mass spectrometry (HR-ESI-MS) and nuclear
magnetic resonance (NMR) measurement.
Immunofluorescence assay
Vero cells in a 24-well plate were infected with
DENV-2 and added with BFA. After 48 h, infected
cells were recovered, washed with PBS, and spotted
onto a glass slide. Immunostaining was done as
described previously [11].
Time-of-addition studies
Time-of-addition studies were performed in 96-well plate
cells as follows. (i) Pre-infection assay: Vero cells were
treated with 125 nM BFA or 0.1% DMSO as control for
2 h at 37 °C prior to being washed twice with PBS and in-
fected with DENV-2 at an MOI of 10. After 1.5 h virus ad-
sorption, the cells were washed twice with PBS and
incubated in fresh media for 24 h before ICFs were har-
vested for virus quantification. (ii) During-infection assay:
Vero cells were infected with DENV-2 in the presence of
BFA. After 1.5 h virus adsorption, inoculum was removed
and the cells were washed twice. The cells were then incu-
bated with fresh media for 24 h before ICFs were har-
vested for virus quantification. (iii) After-infection assay:
Vero cells were infected with DENV-2. After virus adsorp-
tion and washing, BFA or 0.1% DMSO as control was
added at seven different time points postinfection (0, 2, 4,
6, 8, 12, and 18 h). The ICFs were harvested at 24 hpi for
virus quantification.
Virus titration and focus reduction assay
Virus titers were determined using Vero cells in 96-well
plates as described previously [11]. In brief, virus stock or
ICFs were diluted tenfold in the MEM and inoculated to
the cells. After 60 min of virus adsorption, the MEM con-
taining 2% FCS and 1.25% methylcellulose was overlaid on
the cells. The cells were then incubated for 2 to 4 days be-
fore subjected to focus staining. For focus staining,
12D11/7E8 monoclonal antibody and HRP-conjugated
goat anti-mouse IgG + M were used as a primary and sec-
ondary antibody, respectively. The infected cells were vi-
sualized with 3,3′-diaminobenzidine, tetrahydrochloride
(DAB). For focus reduction assay, Vero cells in 96-well
plates were infected with DENV-1, 2, 3, 4, ZIKV, or JEV at
an MOI of 0.5 in the presence of BFA at different concen-
trations. After 48 h incubation, ICFs were harvested. A
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hundred microliters of diluted ICFs (100× or 1000× dilu-
tion) was infected into fresh Vero cells in 96-well plates
and incubate for another 2 to 4 days. The cells were then
subjected for focus staining as described above. Experi-
ments were performed twice, duplicating each.
Results and discussion
Identification of antiviral substance in the present study
was part of our drug screening study for new dengue drug
discovery. We employed cell-based assay in combination
with in-house antigen detection ELISA to evaluate anti-
DENV activity. This technique was relatively quick and
can be applied for high-throughput screening.
In initial testing, the crude extract from cultured broth
of fungal strain Penicillium sp. FKI-7127 showed
pronounced inhibition on DENV growth as determined
from the reduction of antigen level in infectious culture
fluid (data not shown). After optimization of culture
condition which gave the highest inhibition or highest
yield, two rounds of fractionation from large-scale
culture broth were performed. Thirty-six final fractions
were collected from HPLC fractionation, and each
fraction was tested for its antiviral activity. We found
that fraction #17 that showed the highest peak in
chromatogram (Fig. 1a) is the active fraction.
Inhibitory effect and cytotoxicity of fraction #17 were
further evaluated in increasing dilution (Fig. 1b). Fraction
#17 inhibited DENV-2 in a dose-dependent manner. The
50% cytotoxic concentration (CC50) of the fraction after
5 days of simultaneous incubation was > 16×, the lowest
dilution tested.
We next performed the identification of active com-
ponents in fraction #17. Using HR-ESI-MS and NMR
methods, brefeldin A was revealed as an active compound
(Fig. 1c).
To confirm antiviral activity of BFA, we purchased BFA
(Wako, Japan) and performed virus titration and immu-
nofluorescence assay (IFA). BFA effectively inhibited
DENV-2 growth as determined by virus titer. At a concen-
tration of 250 nM, no virus was detected both at 24 and
48 h postinfection (Fig. 2a). Half maximal inhibitory
Fig. 1 Identification of brefeldin A as DENV inhibitor. a Fractions of aqueous residue of cultured broth were applied to HPLC. HPLC chromatogram is
shown, whereas peak of active molecule (fraction #17) was indicated with an arrow. b Vero cells in 96-well plates were infected with DENV at an MOI
of 0.03 in the presence of fraction #17 with increasing dilutions. The cells were incubated for 5 days at 37 °C in 5% CO2 after which ICFs were harvested
and subjected for antigen detection ELISA. In separated experiments, Vero cells in 96-well plates were treated with the fractions with increasing
dilutions without virus infection. After 5 days incubation, cell viability was determined by MTT assay as described in the “Materials and methods”
section. The error bars represent standard deviation from the means of the results from triplicate determination. c By HR-ESI-MS and NMR methods,
the fraction #17 was identified as brefeldin A. Structural formula of BFA is depicted
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concentration (IC50) value and CC50 of BFA at 48 h post-
infection were 54.6 ± 0.9 and 2000 nM, respectively
(Table 1). In line with virus titration results, IFA staining
showed significantly decreased viral protein level by
addition of BFA at concentrations of 62.5 and 125 nM (as
indicated by green fluorescence) suggesting that DENV-2
replication was strongly inhibited (Fig. 2b). Taken together,
these results demonstrated BFA isolated from fungal
strain Penicillium sp. FKI-7127 as an inhibitory agent
against DENV.
BFA is a fungal secondary metabolite which was first
isolated from Penicillium decumbens [12]. BFA has




DENV-1 DENV-2 DENV-3 DENV-4 ZIKV JEV
61.3 ± 13.5 54.6 ± 0.9 57.9 ± 0.1 65.7 ± 6.3 54.8 ± 0.4 58.4 ± 0.3 2000
All calculation was performed by using GraphPad Prism software. All values are the results from two independent experiments
aIC50—50% inhibitory concentration of BFA were calculated from the results of the virus titer determined by focus-forming assay
bCC50—50% cytotoxic concentration of BFA were calculated from the dose-response curve
Fig. 2 Identification of anti-DENV activity of brefeldin A by virus titration and immunofluorescence assay or IFA. a Vero cells in 96-well plates were
infected with DENV at an MOI of 0.5 in the presence of compound at indicated concentrations or 0.1% DMSO. After 24 h or 48 h incubation, ICF
was harvested and virus titer was determined by focus assay as described in the “Materials and methods” section. In separated experiments, Vero
cells in 96-well plates were treated with the compounds at different concentrations without virus infection. After 24 h or 48 h incubation, cell
viability was determined by MTT assay as described in the “Materials and methods” section. b Vero cells in 24-well plates were infected with DENV
at an MOI of 0.5 and added with the compounds at indicated concentrations. After 48 h incubation, the cells were recovered, spotted onto glass
slides, and stained with 12D11 monoclonal antibody which react to viral envelope protein
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various biological actions including antitumor and
antibacterial activities [13]. BFA has also been re-
ported to have antiviral activities against some viruses
including poliovirus [14] and Rotavirus [15]. Recently,
Zhou et al. demonstrated the inhibitory effect of BFA
on Japanese encephalitis virus (JEV) in BHK-21 cells
[16]. To our knowledge, this is the first report to
demonstrate antiviral activity of BFA on DENV.
Antiviral activity of BFA against all DENV serotypes
as well as two related viruses including ZIKV and JEV
was also analyzed by focus reduction assay. Addition
of BFA reduced focus number in a dose-dependent
manner which indicates virus inhibition. BFA inhib-
ited not only DENV-2 but also all other serotypes.
Furthermore, strong inhibition of ZIKV and JEV by
BFA was also demonstrated (Fig. 3). Determined by
virus titer, the EC50 of BFA against DENV-1, 3, and
4, ZIKV, and JEV at 48 h postinfection/treatment
were 61.32 ± 13.5, 57.9 ± 0.1, 65.7 ± 6.3, 54.8 ± 0.4, and
58.4 ± 0.3 nM, respectively (Table 1).
In order to identify the window in the DENV repli-
cation cycle when BFA exerts its antiviral effect, time-
of-addition studies were performed in different treat-
ments (Fig. 4a). During a single flavivirus life cycle,
viral proteins are translated from genomic RNA in
the first 1–5 h postinfection (hpi) followed by viral
RNA synthesis which occurs after 5 hpi and progeny
virus assembly and release after 12 hpi [17]. As
shown in Fig. 4b, BFA does not interfere in the
DENV entry process in the host cells. A significant
reduction of the DENV titer was observed when BFA
was added at the 0-hpi up to 4-hpi time points. After
4 hpi, inhibitory effect of BFA was gradually reduced.
Addition of BFA at 18 hpi resulted in complete loss
of inhibition of DENV replication. These results sug-
gested that BFA inhibits DENV at an early phase in
the viral replication cycle that occurs after viral entry.
The time-of-addition study results are in line with
an already known mode of action of BFA. BFA has
been known to inhibit protein transport from the
endoplasmic reticulum (ER) to the Golgi apparatus
indirectly by interfering with the function of the Golgi
apparatus [18]. BFA disturbs maturation and egress of
herpes simplex virus particles during infection [19].
BFA has also been reported to interfere processing
and secretion of the envelope of glycoproteins of
HIV-1 in T-lymphoblast cells leading to inhibition of
viral particle formation [20]. In case of poliovirus,
BFA inhibits viral RNA synthesis by preventing the
formation of secretory vesicles [21]. We speculate
that, like other enveloped viruses, BFA inhibits the
maturation of the DENV, ZIKV, and JEV by directly
blocking the trafficking of glycoprotein from the ER
to Golgi apparatus leading to the prevention of
formation and release of the viruses from infected
cells. In addition in our study, no inhibitory effect of
BFA on DENV was shown in C6/36 cells (data not
shown) indicating that BFA could not block intracel-
lular protein transport in mosquito cell line.
Despite the fact that BFA possesses antiviral activity as
demonstrated in this study and other previous studies, its
toxicity would become a crucial issue in order to develop
it as antiviral agents. Toxicity of BFA indeed is not unex-
pected because it targets Golgi apparatus which eventually
causes cell death. However, BFA could be served as a lead
compound. In the future, it can be structurally and pheno-
typically optimized by reducing its toxicity. Furthermore,
its antiviral activity can also be improved through deriva-
tive analyses or another approaches.
Aside from its antiviral property, mechanism of
disruption of the proper vesicular transport between ER
and Golgi by BFA which is a critical step for the viral
replication and release could provide a new tool to
characterize the lifecycle of the virus. It is also possible
to help researchers develop novel inhibitors of DENV
and other viruses.
Fig. 3 Inhibitory effect of BFA on all DENV serotypes, ZIKV, and JEV.
Vero cells in 96-well plates were infected with DENV-1, 2, 3, and 4,
ZIKV, or JEV in the presence of BFA at indicated concentration or
0.1% DMSO. Forty-eight hours after infection/treatment, ICFs were
harvested and then infected into fresh cells for focus reduction assay
as described in the “Materials and methods” section. The image
shown is a representative result from two experiments
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Conclusion
In conclusion, here we isolated, identified, and character-
ized an anti-DENV agent of fungus-derived BFA which is
potentially used as a lead compound for drug develop-
ment of anti-DENV and other related viruses. Fungal sec-
ondary metabolites are a potential and valuable source in
drug screening for the development of antiviral agents.
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Fig. 4 Time-of-addition studies. a Schematic illustration of time-of-addition studies for treatment with BFA. Vero cells in 96-well plates were
treated with 125 nM BFA at different time points before, during, and after DENV infection (MOI of 5). For after-infection assay, BFA was added at
seven different time points after virus exposure. b After 24 h postinfection, released virus titer was determined by focus assay as described in the
“Materials and methods” section. Error bars represent standard errors of two independent experiments
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